ArticleDigestive diseases and sciences2025
Using Machine Learning Methods to Develop Diagnostic and Prognostic mRNA Signatures for Pancreatic Cancer in Plasma Small Extracellular Vesicles.
Article in Digestive diseases and sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Artificial intelligence and extracellular vesicles in oncology: towards tumor diagnosis, prediction, and therapy.Drug delivery · 2026Review
- Artificial intelligence virtual extracellular vesicles (AIVEVs).Bioactive materials · 2026Review
- Exploring the Role of Extracellular Vesicles in Pancreatic and Hepatobiliary Cancers: Advances Through Artificial Intelligence.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed in advanced stage due to the absence of effective diagnostic biomarkers. Small extracellular vesicles (sEVs) have recently emerged as potential clinical biomarkers in liquid biopsy. Our study aimed to explore sEV mRNA biomarkers for PDAC diagnosis and identify relevant markers that could guide the prognosis of PDAC patients.
methodsWe analyzed mRNA sequencing of plasma sEVs from 100 participants and employed four machine learning techniques to create and assess the diagnostic models. Partial plasma sEV mRNAs were identified by all four feature extraction methods and used to construct diagnostic model. We also evaluated the predictive value of the model for the survival prognosis of PDAC patients.
resultsCombined with carbohydrate antigen 19-9 (CA19-9), the 4 sEV mRNAs diagnostic signature (d-signature) could well differentiate PDAC patients from non-PDAC individuals, healthy control individuals, and benign pancreatic disease patients with an area under the curve (AUC) of 0.902, 0.971, and 0.845 in training cohort and AUC of 0.803, 0.938, and 0.762 in validation cohort. Furthermore, Cox regression analysis indicated that the score constructed based on the sEV mRNA signature was an independent adverse prognostic factor for survival prognosis of PDAC.
conclusionsOur study demonstrated the potential utility of the sEV mRNA d-signature in the diagnosis of PDAC via machine learning methods. Simultaneously, the score from this diagnostic model exhibited a significant correlation with adverse outcome in PDAC patients. This provided a novel non-invasive sEV mRNA signature for clinical diagnosis and prognostic evaluation of PDAC patients.
Indexed as
Identifiers
40172749What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.